Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Alpine Immune Sciences Inc is a biotechnology business based in the US. Alpine Immune Sciences shares (ALPN) are listed on the NASDAQ and all prices are listed in US Dollars. Alpine Immune Sciences employs 57 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$10.94|
|52-week range||$7.21 - $16.37|
|50-day moving average||$10.68|
|200-day moving average||$10.18|
|Wall St. target price||$20.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.46|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||N/A|
|1 month (2021-09-24)||5.60%|
|3 months (2021-07-26)||29.62%|
|6 months (2021-04-26)||-12.90%|
|1 year (2020-10-26)||42.63%|
|2 years (2019-10-25)||287.94%|
|3 years (2018-10-26)||120.12%|
|5 years (2016-10-26)||78.76%|
|Revenue TTM||$18 million|
|Gross profit TTM||$-17,850,000|
|Return on assets TTM||-16.5%|
|Return on equity TTM||-113.73%|
|Market capitalisation||$308.1 million|
TTM: trailing 12 months
There are currently 474,175 Alpine Immune Sciences shares held short by investors – that's known as Alpine Immune Sciences's "short interest". This figure is 27.6% down from 654,829 last month.
There are a few different ways that this level of interest in shorting Alpine Immune Sciences shares can be evaluated.
Alpine Immune Sciences's "short interest ratio" (SIR) is the quantity of Alpine Immune Sciences shares currently shorted divided by the average quantity of Alpine Immune Sciences shares traded daily (recently around 144565.54878049). Alpine Immune Sciences's SIR currently stands at 3.28. In other words for every 100,000 Alpine Immune Sciences shares traded daily on the market, roughly 3280 shares are currently held short.
However Alpine Immune Sciences's short interest can also be evaluated against the total number of Alpine Immune Sciences shares, or, against the total number of tradable Alpine Immune Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alpine Immune Sciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Alpine Immune Sciences shares in existence, roughly 20 shares are currently held short) or 0.0309% of the tradable shares (for every 100,000 tradable Alpine Immune Sciences shares, roughly 31 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alpine Immune Sciences.
Find out more about how you can short Alpine Immune Sciences stock.
We're not expecting Alpine Immune Sciences to pay a dividend over the next 12 months.
Alpine Immune Sciences's shares were split on a 1:4 basis on 24 July 2017. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alpine Immune Sciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Alpine Immune Sciences shares which in turn could have impacted Alpine Immune Sciences's share price.
Over the last 12 months, Alpine Immune Sciences's shares have ranged in value from as little as $7.21 up to $16.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alpine Immune Sciences's is 1.621. This would suggest that Alpine Immune Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Alpine Immune Sciences, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington. .
Steps to owning and managing Valkyrie Bitcoin Strategy ETF units.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.